» Articles » PMID: 15249473

Narcotic and Benzodiazepine Use After Withdrawal of Life Support: Association with Time to Death?

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2004 Jul 14
PMID 15249473
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine whether the dose of narcotics and benzodiazepines is associated with length of time from mechanical ventilation withdrawal to death in the setting of withdrawal of life-sustaining treatment in the ICU.

Design: Retrospective chart review.

Setting: University-affiliated, level I trauma center.

Patients: Consecutive critically ill patients who had mechanical ventilation withdrawn and subsequently died in the ICU during two study time periods.

Results: There were 75 eligible patients with a mean age of 59 years. The primary ICU admission diagnoses included intracranial hemorrhage (37%), trauma (27%), acute respiratory failure (27%), and acute renal failure (20%). Patients died during a median of 35 min (range, 1 to 890 min) after ventilator withdrawal. On average, 16.2 mg/h opiates in morphine equivalents and 7.5 mg/h benzodiazepine in lorazepam equivalents were administered during the time period starting 1 h before ventilator withdrawal and ending at death. There was no statistically significant relationship between the average hourly narcotic and benzodiazepine use during the 1-h period prior to ventilator withdrawal until death, and the time from ventilator withdrawal to death. The restriction of medication assessment in the last 2 h of life showed an inverse association between the use of benzodiazepines and time to death. For every 1 mg/h increase in benzodiazepine use, time to death was increased by 13 min (p = 0.015). There was no relationship between narcotic dose and time to death during the last 2 h of life (p = 0.11).

Conclusions: We found no evidence that the use of narcotics or benzodiazepines to treat discomfort after the withdrawal of life support hastens death in critically ill patients at our center. Clinicians should strive to control patient symptoms in this setting and should document the rationale for escalating drug doses.

Citing Articles

Evidence Guiding Withdrawal of Mechanical Ventilation at the End of Life: A Review.

Mazzu M, Campbell M, Schwartzstein R, White D, Mitchell S, Fehnel C J Pain Symptom Manage. 2023; 66(3):e399-e426.

PMID: 37244527 PMC: 10527530. DOI: 10.1016/j.jpainsymman.2023.05.009.


Palliative extubation experience in a community hospital in southern Brazil.

Antonio A, Antonio J Rev Assoc Med Bras (1992). 2023; 69(6):e20230208.

PMID: 37194907 PMC: 10185055. DOI: 10.1590/1806-9282.20230208.


End-of-Life and Palliative Care in a Critical Care Setting: The Crucial Role of the Critical Care Pharmacist.

Sloss R, Mehta R, Metaxa V Pharmacy (Basel). 2022; 10(5).

PMID: 36136840 PMC: 9498871. DOI: 10.3390/pharmacy10050107.


Emotional impact of compassionate extubation on respiratory therapists and nurses: A pilot study.

Kaur R, Chen E, Faizi A, Lamadrid V, Vines D, Scott J Can J Respir Ther. 2022; 58:115-120.

PMID: 35928235 PMC: 9318268. DOI: 10.29390/cjrt-2022-022.


Neonatal End-of-Life Symptom Management.

Cortezzo D, Meyer M Front Pediatr. 2020; 8:574121.

PMID: 33042931 PMC: 7516797. DOI: 10.3389/fped.2020.574121.